ChartMill · Aug 19, 2026
CG Oncology (NASDAQ:CGON) Flaunts a Perfect Technical Breakout Setup
CG Oncology (CGON) earns perfect 10/10 technical and setup ratings, near highs with defined breakout entry—top breakout setup stock.
CG
NASDAQ · CGON
CG Oncology, Inc. Common stock
Healthcare · Biotechnology
$64.06
Up+$2.07 (+3.23%)
Updated Nov 4, 2026, 6:16 PM
SID Score
5.2/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 3.12B
- P/E ratio
- -29.65
- Dividend yield
- 0.00%
- 52-week range
- $35.80 – $80.97
- Volume
- 725.15K
- Avg. volume
- 990.79K
Price performance · CGON
CGON price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
CGON closed at $64.06 after 21 trading sessions, up 0.66% for the selected period.
- Last close
- $64.06
- Period change
- +0.66%
- Period low
- $59.85
- Period high
- $64.68
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $62.52 | $65.785 | $62.35 | $64.06 | 725.15K |
| Nov 2, 2026 | $64.18 | $64.68 | $61.01 | $61.96 | 1.28M |
| Oct 30, 2026 | $63.00 | $65.545 | $60.625 | $64.68 | 870.33K |
| Oct 29, 2026 | $64.53 | $65.74 | $63.08 | $63.47 | 782.62K |
| Oct 28, 2026 | $62.53 | $64.115 | $62.30 | $63.96 | 944.3K |
| Oct 27, 2026 | $61.46 | $64.13 | $59.96 | $62.94 | 709.34K |
| Oct 26, 2026 | $61.76 | $62.795 | $61.06 | $61.56 | 880.16K |
| Oct 23, 2026 | $62.36 | $62.36 | $59.86 | $61.71 | 1.06M |
| Oct 22, 2026 | $61.95 | $63.185 | $61.395 | $62.54 | 579.52K |
| Oct 21, 2026 | $62.43 | $63.57 | $61.27 | $62.24 | 530.14K |
| Oct 20, 2026 | $60.16 | $62.71 | $60.16 | $61.93 | 766.68K |
| Oct 19, 2026 | $60.44 | $61.25 | $59.22 | $59.96 | 1.22M |
| Oct 16, 2026 | $61.86 | $62.00 | $59.37 | $59.85 | 1.08M |
| Oct 15, 2026 | $62.70 | $63.24 | $60.96 | $61.86 | 1.19M |
| Oct 14, 2026 | $62.48 | $63.44 | $61.27 | $61.84 | 1.1M |
| Oct 13, 2026 | $61.92 | $63.8461 | $61.52 | $62.40 | 1.19M |
| Oct 12, 2026 | $63.43 | $64.15 | $62.68 | $63.13 | 660.63K |
| Oct 9, 2026 | $62.97 | $65.18 | $62.88 | $63.82 | 516.54K |
| Oct 8, 2026 | $61.65 | $63.71 | $61.11 | $63.26 | 910.31K |
| Oct 7, 2026 | $62.68 | $63.64 | $61.90 | $62.38 | 621.82K |
| Oct 6, 2026 | $69.17 | $69.17 | $63.19 | $63.64 | 774.38K |
Latest CGON news
The latest Smart Investors Daily articles mentioning CGON.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CGON research
Overview
Company profile and research snapshot.
Company profile
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $69.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Piper Sandler | Overweight | — |
| Aug 7, 2026 | RBC Capital | Outperform | — |
| Aug 7, 2026 | Truist Securities | Buy | — |
| May 19, 2026 | Wolfe Research | Peer Perform | — |
| May 18, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 27, 2026
What Analysts Are Saying About CG Oncology Stock
Benzinga · Feb 27, 2026
HC Wainwright & Co. Maintains Buy on CG Oncology, Raises Price Target to $80
HC Wainwright & Co. analyst Andres Y. Maldonado maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $75 to $80.
Benzinga · Feb 27, 2026
CG Oncology Q4 Earnings Report: What Investors Need to Know
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
